HI
UBX

Harbour Investments’s Unity Biotechnology UBX Stock Holding History

Harbour Investments’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-678
Closed -$1.11K – 3374
2024
Q1 		$1.11K Buy
+678
New +$1.18K ﹤0.01% 2906

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harbour Investments's UBX Position: Q2 2024 in Review

Harbour Investments sold out of Unity Biotechnology (UBX) in Q2 2024, closing a stake of 678 shares — an estimated $1.11K sold.

Harbour Investments first reported a position in UBX in Q1 2024 and held it in 1 quarter. The position peaked at $1.11K in Q1 2024. 39 funds tracked by Wall St. Rank hold UBX as of Q2 2024.

  • Harbour Investments reported no remaining Unity Biotechnology position as of Q2 2024 after selling out during the quarter.
  • Harbour Investments sold 678 Unity Biotechnology shares in Q2 2024, an estimated $1.11K.
  • Harbour Investments first reported a position in Unity Biotechnology in Q1 2024 and held it in 1 quarter.
  • Harbour Investments's Unity Biotechnology position peaked at $1.11K in Q1 2024.
  • 39 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2024.

Based on Harbour Investments's 13F filing for Q2 2024, filed 26 Jul 2024.